No Picture
Trading Ideas

Oil Sinks With Rebound in Libyan Output Adding to Market Gloom

(Bloomberg) — Crude slid after a key Libyan oil field resumed production, threatening to unleash barrels into a market where demand is already lackluster.U.S. oil futures fell as much as 3% on Thursday after trading in a tight range this week. The Messla oil field and Sarir refinery in eastern Libya resumed production after a technical problem forced a shutdown. Meanwhile, rising global coronavirus cases and reports of layoffs at companies from Wells Fargo & Co. to Walgreen Boots Alliance Inc. are dampening the potential of a demand recovery later this year.“The global market is going to have a difficult …read more […]

No Picture
Trading Ideas

3 Small-Cap Stocks Under $6 That Could See Over 70% Gains

As the number of new COVID-19 cases climbs at a record pace, the stock market isn’t just trudging along, it’s charging forward. Given this clear disconnect, finding compelling plays can feel like guesswork. The adrenalin junkies among the Wall Street observers, however, are turning to small-caps.Out on the Street, these names with market capitalizations landing below $2 billion are known for their volatility as they are prone to very extreme movements. That being said, small-cap stocks boast huge growth prospects that their larger counterparts simply don’t offer. Additionally, these often younger companies tend to fly under-the-radar, meaning that the potential …read more […]

No Picture
Trading Ideas

Bed Bath Drops 9% In Pre-Market As Sales Sink 49%; Merrill Lynch Raises PT

Shares in Bed Bath & Beyond (BBBY) plunged 9% in pre-market trading after the home goods retailer reported a 49% decline in net sales in the first quarter due to temporary store closures during the coronavirus pandemic.The stock dropped to $9.45 in Thursday’s pre-market trading as the retailer announced that it will close about 200 of its stores over the next two years to cut costs. Net sales in the first quarter dropped 49% to $1.3 billion year-on-year falling short of the $1.39 billion estimated by analysts. Bed Bath reported an adjusted net loss of $1.96 per diluted share for …read more […]

No Picture
Trading Ideas

Walgreens Ends Buybacks, Cuts Jobs as Profit Misses; Shares Fall

(Bloomberg) — Walgreens Boots Alliance Inc. reported worse-than-expected results for the third quarter, saying it plans to cut 4,000 jobs and suspend share buybacks as it wrestles with the effects of the coronavirus pandemic on it business.The drugstore giant posted a loss of $1.71 billion, or $1.95 a share. On an adjusted basis, earnings per share came to 83 cents. Analysts surveyed by Bloomberg expected adjusted earnings of $1.19 a share.Key InsightsDrugstores are seeing rapid shifts in U.S. consumer behavior driven by Covid-19. People rushed to stock up on prescriptions and toilet paper in March. Sales were essentially flat compared …read more […]

No Picture
Trading Ideas

Costco June Sales Beat Estimates As Shoppers Go Online; Top Analyst Raises PT

Costco’s (COST) comparable sales rose 11.5% in June fueled by e-commerce revenue growth.Analysts had estimated an advance of about 4.2% in comparable sales for the five weeks ended July 5. E-commerce sales were up almost 86% during the reported period. On a geographical breakdown comparable sales advanced 11% in the U.S., 8.4% in Canada, and 18% in other global markets.In the 44 weeks ended July 5, the food retail chain reported net sales of $136.37 billion, an increase of 8.1% year-on-year. Costco had in recent months suffered from a sales drop as stay-at-home orders and social distancing restrictions have led …read more […]

No Picture
Trading Ideas

AstraZeneca’s Wins FDA Priority Review For Heart Drug Brilinta

AstraZeneca Plc (AZN) announced on Thursday that the Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted a priority review for its heart treatment Brilinta.The U.S. regulator granted priority review for the drugmaker’s Brilinta (ticagrelor) as a treatment for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA). The FDA action date for the supplemental application, is scheduled for the fourth quarter of 2020.The sNDA was based on results from the Phase III THALES trial, which showed that the treatment of aspirin in combination with …read more […]